These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 26860778)
1. Effects of Iron Overload on Cardiac Calcium Regulation: Translational Insights Into Mechanisms and Management of a Global Epidemic. Khamseekaew J; Kumfu S; Chattipakorn SC; Chattipakorn N Can J Cardiol; 2016 Aug; 32(8):1009-16. PubMed ID: 26860778 [TBL] [Abstract][Full Text] [Related]
2. Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy? Wijarnpreecha K; Kumfu S; Chattipakorn SC; Chattipakorn N Hemoglobin; 2015; 39(1):9-17. PubMed ID: 25572185 [TBL] [Abstract][Full Text] [Related]
3. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Oudit GY; Sun H; Trivieri MG; Koch SE; Dawood F; Ackerley C; Yazdanpanah M; Wilson GJ; Schwartz A; Liu PP; Backx PH Nat Med; 2003 Sep; 9(9):1187-94. PubMed ID: 12937413 [TBL] [Abstract][Full Text] [Related]
4. Effects of the iron chelator deferiprone and the T-type calcium channel blocker efonidipine on cardiac function and Ca Khamseekaew J; Kumfu S; Palee S; Wongjaikam S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N Cell Calcium; 2018 Jun; 72():18-25. PubMed ID: 29748130 [TBL] [Abstract][Full Text] [Related]
5. Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update. Gordan R; Wongjaikam S; Gwathmey JK; Chattipakorn N; Chattipakorn SC; Xie LH Heart Fail Rev; 2018 Sep; 23(5):801-816. PubMed ID: 29675595 [TBL] [Abstract][Full Text] [Related]
6. T-type and L-type Calcium Channel Blockers for the Treatment of Cardiac Iron Overload: An Update. Kumfu S; Chattipakorn SC; Chattipakorn N J Cardiovasc Pharmacol; 2017 Nov; 70(5):277-283. PubMed ID: 28777254 [TBL] [Abstract][Full Text] [Related]
7. Females Are Protected From Iron-Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress. Das SK; Patel VB; Basu R; Wang W; DesAulniers J; Kassiri Z; Oudit GY J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28115312 [TBL] [Abstract][Full Text] [Related]
8. Current and future treatment strategies for iron overload cardiomyopathy. Wongjaikam S; Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N Eur J Pharmacol; 2015 Oct; 765():86-93. PubMed ID: 26291660 [TBL] [Abstract][Full Text] [Related]
9. Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. Das SK; Wang W; Zhabyeyev P; Basu R; McLean B; Fan D; Parajuli N; DesAulniers J; Patel VB; Hajjar RJ; Dyck JR; Kassiri Z; Oudit GY Sci Rep; 2015 Dec; 5():18132. PubMed ID: 26638758 [TBL] [Abstract][Full Text] [Related]
10. Iron overload and apoptosis of HL-1 cardiomyocytes: effects of calcium channel blockade. Chen MP; Cabantchik ZI; Chan S; Chan GC; Cheung YF PLoS One; 2014; 9(11):e112915. PubMed ID: 25390893 [TBL] [Abstract][Full Text] [Related]
11. The effects of iron overload on mitochondrial function, mitochondrial dynamics, and ferroptosis in cardiomyocytes. Sumneang N; Siri-Angkul N; Kumfu S; Chattipakorn SC; Chattipakorn N Arch Biochem Biophys; 2020 Feb; 680():108241. PubMed ID: 31891670 [TBL] [Abstract][Full Text] [Related]
12. Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy. Das SK; Zhabyeyev P; Basu R; Patel VB; Dyck JRB; Kassiri Z; Oudit GY Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29208771 [TBL] [Abstract][Full Text] [Related]
13. Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration. Moon SN; Han JW; Hwang HS; Kim MJ; Lee SJ; Lee JY; Oh CK; Jeong DC Pediatr Cardiol; 2011 Oct; 32(7):947-52. PubMed ID: 21656238 [TBL] [Abstract][Full Text] [Related]